title: Comparative effects of atenolol versus celiprolol on serum lipids and blood pressure in hyperlipidemic and hypertensive subjects.
abstract: Antihypertensive drugs may affect serum lipoprotein levels in mixed populations but data in hyperlipidemic patients are scanty. Atenolol versus celiprolol effects on serum lipoproteins were compared in 159 hyperlipoproteinemic hypertensive patients. This was a randomized, double-blind, parallel-group, positive-controlled multicenter trial with centralized lipoprotein laboratory and diet constancy monitoring. Blood pressure reduction and serum lipoprotein and apoprotein levels were monitored for 3 months. Both drugs reduced systolic and diastolic blood pressures. Atenolol had greater effects than celiprolol on diastolic pressure, but effects on systolic blood pressure were not different. Patients receiving atenolol had lower serum high-density lipoprotein cholesterol levels and higher low-density lipoprotein/high-density lipoprotein cholesterol ratios, whereas patients treated with celiprolol showed no contrasting changes. These differences in lipoprotein levels between drug treatment groups were statistically significant at weeks 9 and 12. The difference between drug treatments was also significant if the values of the 9- and 12-week visits were averaged. Patients taking atenolol had statistically significantly higher serum levels of total cholesterol, triglycerides and apoprotein B at 9 weeks. These divergent directional changes were consistent throughout and statistically significantly different between drugs.
authors.affiliation: Lipid and Arteriosclerosis Prevention Clinic, University of Kansas, Kansas City.
authors.forename: C A
authors.initials: CA
authors.lastname: Dujovne
authors.forename: J
authors.initials: J
authors.lastname: Eff
authors.forename: L
authors.initials: L
authors.lastname: Ferraro
authors.forename: R J
authors.initials: RJ
authors.lastname: Goldstein
authors.forename: A M
authors.initials: AM
authors.lastname: Gotto
authors.forename: W D
authors.initials: WD
authors.lastname: Hall
authors.forename: W S
authors.initials: WS
authors.lastname: Harris
authors.forename: S J
authors.initials: SJ
authors.lastname: Held
authors.forename: A
authors.initials: A
authors.lastname: Herd
authors.forename: D B
authors.initials: DB
authors.lastname: Hunninghake
mesh_terms: D000328:Adult; D000368:Aged; D001262:Atenolol / Q000494:pharmacology* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects*; D017272:Celiprolol / Q000494:pharmacology* / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000150:complications*; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged
chemical_list: D008074:Lipoproteins; D001262:Atenolol; D017272:Celiprolol